| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/18/2001 | CA2377228A1 E4orf4 and pp2a polypeptides, modulators, and mimetics for selectively inducing cell death |
| 01/17/2001 | EP1069137A1 Peptides having thrombospondin-like activity and their therapeutic use |
| 01/17/2001 | EP1069114A2 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 01/17/2001 | EP1068870A1 Antitumor agents |
| 01/17/2001 | EP1068868A2 Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration |
| 01/17/2001 | EP1068357A1 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| 01/17/2001 | EP1068338A2 Enhanced prodrug activation |
| 01/17/2001 | EP1068318A2 Human nucleic acid sequences from prostate tissue |
| 01/17/2001 | EP1068317A2 Human nucleic acid sequences from prostate tumour tissue |
| 01/17/2001 | EP1068308A1 Secreted proteins and polynucleotides encoding them |
| 01/17/2001 | EP1068297A1 Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency |
| 01/17/2001 | EP1068296A1 Methods and compositions for eliciting an immune response to a telomerase antigen |
| 01/17/2001 | EP1068236A1 Human oxidized ldl receptor |
| 01/17/2001 | EP1068233A1 Transcription factors and their use |
| 01/17/2001 | EP1068231A2 Human nucleic acid sequences of normal ovary tissue |
| 01/17/2001 | EP1068224A2 Pharmaceuticals for the imaging of angiogenic disorders |
| 01/17/2001 | EP1068222A1 Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer |
| 01/17/2001 | EP1068195A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1068192A1 Novel crystalline complexes of baccatin iii with imidazole, 2-methylimidazole or isopropanol |
| 01/17/2001 | EP1068180A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloprotenase inhibitors |
| 01/17/2001 | EP1068178A1 NON-PEPTIDE GnRH AGENTS |
| 01/17/2001 | EP1067971A1 Inorganic material for radioactive drug delivery |
| 01/17/2001 | EP1067964A1 Immunomodulatory compositions of mmtv antigens and methods of using same |
| 01/17/2001 | EP1067960A2 A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient |
| 01/17/2001 | EP1067956A2 Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| 01/17/2001 | EP1067955A2 Pharmaceutical compositions comprising erythropoietin for treatment of cancer |
| 01/17/2001 | EP1067944A1 New combined preparation for the treatment of neoplasic diseases or of infectious diseases |
| 01/17/2001 | EP1067941A1 Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate |
| 01/17/2001 | EP1067939A1 Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways |
| 01/17/2001 | EP1067933A1 Semi-synthetic ecteinascidins |
| 01/17/2001 | EP1067932A1 Methods for inhibiting mrp1 |
| 01/17/2001 | EP1067931A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067930A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067929A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067928A1 Methods for inhibiting mrp1 |
| 01/17/2001 | EP1067919A1 Dfmo and sulindac combination in cancer chemoprevention |
| 01/17/2001 | EP1067909A1 Cationic lipid formulation delivering nucleic acid to peritoneal tumors |
| 01/17/2001 | EP1067908A1 Anticancer compositions |
| 01/17/2001 | EP1067894A2 Protease inhibitors |
| 01/17/2001 | EP1067893A2 Human galactosyl transferases |
| 01/17/2001 | EP1043928A4 Methods and compositions for treating and diagnosing tumors using adenosine receptor activated cells |
| 01/17/2001 | EP0983258A4 N-hydroxy 4-sulfonyl butanamide compounds |
| 01/17/2001 | EP0771216B1 Methods and compositions for the specific coagulation of tumoral vasculature |
| 01/17/2001 | EP0750514B1 Immunotherapeutic preparations containing gamma globulins for treating cancerous diseases |
| 01/17/2001 | EP0730590B1 isoxazoline and isoxazole fibrinogen receptor antagonists |
| 01/17/2001 | CN1280616A Method and compositions for inducing tumor-specific cytotoxicity |
| 01/17/2001 | CN1280613A Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor |
| 01/17/2001 | CN1280580A Thienopyrimidine and thienopyridine derivatives useful as anti-cancer agents |
| 01/17/2001 | CN1280572A Inhibiting platelet derivative growth factor and/or quinoline and quinowoline compounds of P56lek tyrosinkinase |
| 01/17/2001 | CN1280568A Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| 01/17/2001 | CN1280137A Erythrocyte-stimulating factor coupling |
| 01/17/2001 | CN1279988A Medicine for curing tumor |
| 01/17/2001 | CN1279978A Ginkgo and gastrodia taber capsule |
| 01/17/2001 | CN1279976A Anti-cancer medicine and its producing method |
| 01/17/2001 | CN1279960A Anti-cancer Chinese medicine and its preparing method |
| 01/17/2001 | CN1279957A Use of puffer liver oil in preparing food for curing poisonous drug dependence |
| 01/17/2001 | CN1279954A Arsenic composite preparation suitable for cancer arterial insertion administration and its preparing method |
| 01/17/2001 | CN1060781C Phosphonomonoester nucleic acids, process for treir preparation, and their use |
| 01/17/2001 | CN1060770C Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof |
| 01/17/2001 | CN1060764C Ortho-substituted benzoylguanidine, preparation method, use as medicine or diagnostic reagent and medicine containing them |
| 01/17/2001 | CN1060763C Urea-substituted benzoylguanidines, process for their preparation, and use and pharmaceutical containing them |
| 01/17/2001 | CN1060659C Pill medicine for cancer and proparation method |
| 01/17/2001 | CN1060653C Medicine for detumescence and anti-cancer |
| 01/16/2001 | US6175023 Synthesis of water soluble 9-dihydro-paclitaxel derivatives from 9-dihydro-13-acetylbaccatin III |
| 01/16/2001 | US6174994 7TM receptor (H2CAA71) |
| 01/16/2001 | US6174993 Short peptides which selectively modulate the activity of serine/threonine kinases |
| 01/16/2001 | US6174913 Treating tumor by administering compounds e.g.:2-acetyl-naphtho(2,3-b)thiophene-4,9-dione; 2,7-diacetyl-naphtho(2,3-b)thiophene-4,9-dione |
| 01/16/2001 | US6174889 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| 01/16/2001 | US6174876 Use of boswellic acid for treating brain tumors |
| 01/16/2001 | US6174873 Oral administration of adenosine analogs |
| 01/16/2001 | US6174726 Method for the immortalization of cells using conditionally transformed helper cells |
| 01/16/2001 | US6174692 Detecting preferential antigen in sample; incubating monoclonal antibody with sample containing preferential antigen and detecting biinding |
| 01/16/2001 | US6174691 Deactivating a preferential tumor glycoprotein or a cell expressing preferential glycoprotein; exposing preferential glycoprotein or cell expressing the preferential glycoprotein to a toxic substance |
| 01/16/2001 | CA2188793C Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof |
| 01/11/2001 | WO2001081364A1 Estra-1,3,5(10)-triene derivatives |
| 01/11/2001 | WO2001002604A1 Use of the krit1 gene in angiogenesis |
| 01/11/2001 | WO2001002594A2 DNA CONSTRUCTS BASED ON THE eIF4A GENE PROMOTER |
| 01/11/2001 | WO2001002571A2 An interleukin-1 receptor antagonist and uses thereof |
| 01/11/2001 | WO2001002569A2 Human immune response molecules |
| 01/11/2001 | WO2001002568A2 Human genes and gene expression products |
| 01/11/2001 | WO2001002567A1 16405 receptor, a g-protein coupled receptor |
| 01/11/2001 | WO2001002557A1 Neurotrophic factor receptor |
| 01/11/2001 | WO2001002556A2 Agents for the diagnosis, prognosis and treatment of malignant diseases |
| 01/11/2001 | WO2001002551A2 Virus like particles, preparation and use in screening and functional genomics |
| 01/11/2001 | WO2001002550A2 Cell death related drug targets in yeast and fungi |
| 01/11/2001 | WO2001002540A2 Adenoviral vectors for treating disease |
| 01/11/2001 | WO2001002440A1 Fusion peptides comprising a peptide ligand domain and a multimerization domain |
| 01/11/2001 | WO2001002439A1 Neovascular-targeted immunoconjugates |
| 01/11/2001 | WO2001002434A1 Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor |
| 01/11/2001 | WO2001002431A1 Recombinant adenovirus |
| 01/11/2001 | WO2001002423A2 2'-guanidinyl-substituted oligonucleotides and gene expression modulation therewith |
| 01/11/2001 | WO2001002413A1 BAFIlOMYCIN DERIVATIVES WITH ANTICANCER ACTIVITY |
| 01/11/2001 | WO2001002412A1 5-nitrofurfural derivatives |
| 01/11/2001 | WO2001002408A1 Novel xanthone compounds, their preparation and use as medicament |
| 01/11/2001 | WO2001002407A2 Taxane derivatives and processes for the preparation thereof |
| 01/11/2001 | WO2001002406A1 Potassium channel blocking agents |
| 01/11/2001 | WO2001002398A1 Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them |
| 01/11/2001 | WO2001002389A1 Crystals of benzimidazole compounds |
| 01/11/2001 | WO2001002388A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 01/11/2001 | WO2001002387A1 N-imidazolylmethyl carboxamides as nitric oxide production inhibitors |